A Novel Ruthenium(II) Complex and its Synergistic Anti-Leukemia Activity with GidA Protein via Dual-Pathway Apoptosis
Antony K T Infanta S1, Thandeeswaran Murugesan2, Anand Raj Dhanapal3
1Bharathiar University, Cancer Therapeutics Lab, Microbial Biotechnology, India, Coimbatore.
Drug Research
|July 27, 2026
Summary
A novel GidA-ruthenium(II) complex shows potent anticancer activity against leukemia cells. This dual-mechanism agent exhibits synergistic effects, inducing apoptosis and offering a promising strategy for refractory leukemia treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- K562 human leukemia cells present a challenge for conventional therapies.
- Developing novel therapeutic agents with enhanced efficacy and reduced side effects is crucial.
Purpose of the Study:
- To evaluate the anticancer activity of a semi-synthetic GidA-ruthenium(II) complex against K562 leukemia cells.
- To investigate the synergistic effects and underlying mechanisms of the GidA-ruthenium(II) complex.
Main Methods:
- Monotherapy and combination therapy evaluations using K562 cells.
- Isobologram analysis to determine synergy.
- Apoptosis and necrosis assays.
- Reactive oxygen species (ROS) level measurements.
Main Results:
- GidA and ruthenium(II) exhibited significant cytotoxicity individually.
- Synergistic anticancer activity was observed in specific GidA-ruthenium(II) combinations, particularly those with higher ruthenium(II) concentrations.
- Synergistic complexes significantly increased apoptosis while minimizing necrosis.
- Ruthenium(II) induced ROS-dependent apoptosis, while GidA acted via ROS-independent pathways.
Conclusions:
- The GidA-ruthenium(II) complex demonstrates potent synergistic anticancer activity against K562 leukemia cells.
- The dual-mechanism action, involving ROS-dependent and independent pathways, offers a novel therapeutic strategy.
- Combination 5 (4×Ru(II):1×GidA) is a promising lead candidate for treating refractory leukemia, potentially overcoming chemotherapy limitations.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...